There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Recursion Pharmaceuticals crashed 90% but JPMorgan upgraded with $11 target implying near tripling. Eli Lilly partnered with Nvidia on a $1B AI drug discovery collaboration using Vera Rubin chips.

Lizzi C. Lee is a fellow on the Chinese economy at Asia Society Policy Institute’s Center for China Analysis (CCA), based in Washington DC, USA. Jing Qian is vice-president of the Asia Society and ...

Feb 4 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug ...

(RTTNews) - IO Biotech (IOBT) has opened the door to a potential merger, asset sale, or even dissolution as it evaluates "a range of strategic alternatives," a move that underscores the pressure ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

As a veteran who was wounded during a mortar attack in Iraq, I’m all too familiar with the fact that our enemies can hit us with little warning. I’ve seen firsthand what happens when we underestimate ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Saudi Arabia is orchestrating an ambitious industrial transformation. Historically defined by oil, the Gulf state is investing in vaccines, biomanufacturing, and genomics with the aim of being a ...

2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...